Anaemia
Adult: 1-5 mg/kg daily for 3-6 mth.
Child: Same as adult dose.
Child: Same as adult dose.
Indications and Dosage
Oral
Anaemia Adult: 1-5 mg/kg daily for 3-6 mth.
Child: Same as adult dose. |
Hepatic Impairment
Severe: Contraindicated.
|
Contraindications
Prostate and breast cancer, nephrosis. Severe hepatic impairment. Pregnancy and lactation.
|
Special Precautions
Patient w/ oedematous conditions (e.g. migraine, seizure disorder, CV disease), DM. Renal and mild to moderate hepatic impairment. Childn.
|
Adverse Reactions
Significant: Benign hepatic tumours, blood lipid changes, mild virilisation, benign prostatic hypertrophy (elderly males), clotting factor alterations.
Nervous: Excitation, insomnia, deepening of voice (female). CV: Coronary artery diseas, peripheral oedema. GI: Nausea, vomiting, diarrhoea. Hepatic: Reversible changes in hepatic function tests (e.g. increased serum bilirubin, alkaline phosphatase and glutamic-oxaloacetic transaminase, increased Bromsulphalein retention). Genitourinary: Increased creatine and creatinine excretion, erectile dysfunction, testicular atrophy and oligospermia, impotence, chronic priapism, testicular disease, epididymitis, bladder irritability, decreased seminal volume, clitoromegaly, menstrual disease, amenorrhea (female). Endocrine: Increased or decreased libido, decreased glucose tolerance, gynecomastia, hirsutism (female). Haematologic: Iron-deficiency anaemia, haemorrhage, leukemia, prolonged prothrombin time (PT). Musculoskeletal: Muscle cramps, increased creatinine phosphokinase, premature closure of epiphyses (childn). Dermatologic: Acne, androgenic alopecia, hyperpigmentation. Others: Chills, oedema, serum electrolytes retention. Potentially Fatal: Peliosis hepatitis, malignant hepatic tumours, cholestatic jaundice w/ hepatic necrosis. |
Monitoring Parameters
Periodically monitor LFT, lipid profile, serum iron and iron binding capacity, Hb and haematocrit levels. Monitor radiologic examination of bones every 6 mth (prepubertal childn); urine and serum Ca, signs of virilisation in female patient treated for breast cancer.
|
Drug Interactions
Increased fluid-retention effect w/ adrenal steroids or ACTH. May enhance anticoagulant effect (e.g. increased INR/PT) of warfarin. May increase hepatotoxic effect of cyclosporine. May enhance hypoglycaemic effect of blood glucose lowering agents. May increase risk of cholestasis of ajmaline.
|
Lab Interference
Decreased thyroxine-binding globulin, T4. Increased resin uptake of T3 and T4.
|
Action
Description: Oxymetholone is an anabolic steroid. It is used to treat anaemia (due to bone marrow failure and decreased RBC production) by increasing erythropoietin and stimulating erythropoiesis. It is also a synthetic derivative of testosterone and can suppress the gonadotropic functions of the pituitary.
|
Chemical Structure
![]() Source: National Center for Biotechnology Information. PubChem Database. Oxymetholone, CID=5281034, https://pubchem.ncbi.nlm.nih.gov/compound/Oxymetholone (accessed on Jan. 22, 2020) |
Storage
Store between 20-25°C.
|
MIMS Class
|
ATC Classification
A14AA05 - oxymetholone ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.
|
References
Anadrol-50 Oxymetholone Tablet (Alaven Pharmaceutical). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/09/2017. Anon. Oxymetholone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/09/2017. Buckingham R (ed). Oxymetholone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/09/2017.
|